Distribution of citrate and citrate infusion rate during donor plasmaphereses

Background: The purpose of this study was to describe the distribution of trisodium‐citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation. Subjects and Methods: Data of 32 regular donors of plasma initially collected for a study published in 2010 were re‐a...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical apheresis Vol. 31; no. 1; pp. 59 - 62
Main Authors Evers, Josef, Taborski, Uwe
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.02.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: The purpose of this study was to describe the distribution of trisodium‐citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation. Subjects and Methods: Data of 32 regular donors of plasma initially collected for a study published in 2010 were re‐analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time. Results: 130 ± 12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated. Conclusion: The total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min. J. Clin. Apheresis 31:59–62, 2016. © 2015 Wiley Periodicals, Inc.
AbstractList The purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation.BACKGROUNDThe purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation.Data of 32 regular donors of plasma initially collected for a study published in 2010 were re-analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time.SUBJECTS AND METHODSData of 32 regular donors of plasma initially collected for a study published in 2010 were re-analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time.130 ± 12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated.RESULTS130 ± 12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated.The total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min.CONCLUSIONThe total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min.
Background: The purpose of this study was to describe the distribution of trisodium‐citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation. Subjects and Methods: Data of 32 regular donors of plasma initially collected for a study published in 2010 were re‐analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time. Results: 130 ± 12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated. Conclusion: The total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min. J. Clin. Apheresis 31:59–62, 2016. © 2015 Wiley Periodicals, Inc.
The purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation. Data of 32 regular donors of plasma initially collected for a study published in 2010 were re-analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time. 130 ± 12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated. The total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min.
Background: The purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing plasma donation. Subjects and Methods: Data of 32 regular donors of plasma initially collected for a study published in 2010 were re-analyzed to determine the amount of citrate received by the donor and the citrate infusion rate (CIR) in mg/kg/min to the donor. Donor plasmaphereses (DP) were performed with the automated Haemonetics plasma collecting system 2 (PCS2). Plasma volume was programmed at 760 ml including AC. CIR was calculated from citrate received by the donors divided by the body weight over time. Results: 130±12 ml TSC was used for 760 ml plasma. An average of 110 ml TSC or 84.6% of citrate load was in collected plasma and not given to the donor. From the difference of 20 ml or 514 mg citrate an average CIR of 0.16 mg/kg/min was calculated. Conclusion: The total amount of citrate received by the donor is minimal and the average CIR is below the critical level of 1 mg/kg/min. J. Clin. Apheresis 31:59-62, 2016. © 2015 Wiley Periodicals, Inc.
Author Taborski, Uwe
Evers, Josef
Author_xml – sequence: 1
  givenname: Josef
  surname: Evers
  fullname: Evers, Josef
  email: dr_evers@hotmail.com
  organization: Octapharma Plasma, Plasmazentrum Aachen, Aachen, Germany
– sequence: 2
  givenname: Uwe
  surname: Taborski
  fullname: Taborski, Uwe
  organization: Octapharma Plasma, Plasmazentrum Aachen, Aachen, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26011445$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtL7DAYhoMoOo4u_ANScKOL6pdL03Ypc7ziDVEENyFtE83YSeYkLeq_N-PoLARdJSHP-5E87zpats4qhLYw7GMAcjCu5T7BDOgSGmAoixRjwMtoADmlKWFZuYbWQxgDQFnSbBWtEQ4YM5YN0OU_Ezpvqr4zziZOJ7XpvOxUIm2z2Bur-zC7_zw1vTf2KWmcdT6ZtjJM5PRZeRVU2EArWrZBbX6tQ3R_fHQ3Ok0vrk_ORocXac0Io6kEXeO6hgZrYKxRrOBNTghrcp5zQnWleFVlQLmSlSRMU0ZKruNHKC-KSjI6RLvzuVPv_vcqdGJiQq3aVlrl-iBwzqHgFIoZuvMDHbve2_i6SGUcKJTR0hBtf1F9NVGNmHozkf5dfIuKwN4cqL0LwSu9QDCIWQkiliA-S4jswQ82ipQzwVGnaf9KvJpWvf8-WpyPDr8T6TwR61Nvi4T0L4LnNM_Ew9WJeLw5ZfSG3gpOPwA1M6Vs
CitedBy_id crossref_primary_10_1016_j_bonr_2018_100188
crossref_primary_10_1111_vox_13512
crossref_primary_10_1016_j_transci_2017_04_001
crossref_primary_10_5301_ijao_5000589
crossref_primary_10_1002_jca_21626
crossref_primary_10_1111_trf_15244
crossref_primary_10_1111_trf_13907
crossref_primary_10_1136_bmjopen_2024_085786
crossref_primary_10_1002_jca_22025
crossref_primary_10_35754_0234_5730_2024_69_2_153_162
Cites_doi 10.1046/j.1537-2995.1999.39111266.x
10.1046/j.1537-2995.2001.41091165.x
10.1159/000317092
10.1002/jca.21222
10.1016/j.bone.2009.11.008
10.1002/1098-1101(2000)15:4<230::AID-JCA3>3.0.CO;2-B
10.1159/000357991
ContentType Journal Article
Copyright 2015 Wiley Periodicals, Inc.
2016 Wiley Periodicals, Inc.
Copyright_xml – notice: 2015 Wiley Periodicals, Inc.
– notice: 2016 Wiley Periodicals, Inc.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
DOI 10.1002/jca.21403
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1098-1101
EndPage 62
ExternalDocumentID 3919214091
26011445
10_1002_jca_21403
JCA21403
ark_67375_WNG_ZPH43P3R_6
Genre shortCommunication
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6P
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
XG1
XV2
ZGI
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
K9.
7X8
ID FETCH-LOGICAL-c4243-a0fc1cc0d1f044de486d7224d767623fbe6bb5036eaba24f34296f2453688ba43
IEDL.DBID DR2
ISSN 0733-2459
1098-1101
IngestDate Fri Jul 11 01:38:51 EDT 2025
Sun Jul 13 04:14:18 EDT 2025
Thu Apr 03 06:56:42 EDT 2025
Tue Jul 01 03:59:24 EDT 2025
Thu Apr 24 23:06:05 EDT 2025
Wed Jan 22 16:25:35 EST 2025
Wed Oct 30 09:50:00 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords citrate infusion rate
citrate
citrate toxicity
plasmapheresis
apheresis
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2015 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4243-a0fc1cc0d1f044de486d7224d767623fbe6bb5036eaba24f34296f2453688ba43
Notes ArticleID:JCA21403
ark:/67375/WNG-ZPH43P3R-6
istex:B38C518CEE8509A451C86FF25846391DDC81795B
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 26011445
PQID 1756030973
PQPubID 1006360
PageCount 4
ParticipantIDs proquest_miscellaneous_1760863084
proquest_journals_1756030973
pubmed_primary_26011445
crossref_primary_10_1002_jca_21403
crossref_citationtrail_10_1002_jca_21403
wiley_primary_10_1002_jca_21403_JCA21403
istex_primary_ark_67375_WNG_ZPH43P3R_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2016
PublicationDateYYYYMMDD 2016-02-01
PublicationDate_xml – month: 02
  year: 2016
  text: February 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Worcester
PublicationTitle Journal of clinical apheresis
PublicationTitleAlternate J. Clin. Apheresis
PublicationYear 2016
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher 2012;27:117-125.
Amrein K, Katschnig C, Sipurzynski S, Stojakovic T, Lanzer G, Stach E, Pieber TR, Dobnik H. Apheresis affects bone and mineral metabolism. Bone 2010;46:789-795.
Evers J, Betz J, Blankenburg T, Engelen T, Hansen M, Laitinen T, Taborski U. Influence of NaCl 0.9% infusion during plasmaphereses on IgG content in plasma. Transfus Med Hemother 2010;37:191-194.
Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitmann SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001;41:1166-1171.
Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Klüter H. Clinically relevant hypokalemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apher 2000;15:230-235.
Beeck H, Becker T, Kiessig ST, Kaeser R, Wolter K, Hellstern P. The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study. Transfusion 1999;39:1266-1270.
Diekamp U, Gneißl J, Rabe A, Kiessig ST. Donor hemovigilance during preparatory plasmapheresis. Transfus Med Hemother 2014;41:123-133.
2015
2010; 37
2012; 27
2010; 46
2014; 41
2000; 15
2010
1999; 39
2001; 41
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_10_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_3_1
e_1_2_6_11_1
e_1_2_6_2_1
References_xml – reference: Beeck H, Becker T, Kiessig ST, Kaeser R, Wolter K, Hellstern P. The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study. Transfusion 1999;39:1266-1270.
– reference: Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Klüter H. Clinically relevant hypokalemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apher 2000;15:230-235.
– reference: Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher 2012;27:117-125.
– reference: Diekamp U, Gneißl J, Rabe A, Kiessig ST. Donor hemovigilance during preparatory plasmapheresis. Transfus Med Hemother 2014;41:123-133.
– reference: Amrein K, Katschnig C, Sipurzynski S, Stojakovic T, Lanzer G, Stach E, Pieber TR, Dobnik H. Apheresis affects bone and mineral metabolism. Bone 2010;46:789-795.
– reference: Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitmann SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001;41:1166-1171.
– reference: Evers J, Betz J, Blankenburg T, Engelen T, Hansen M, Laitinen T, Taborski U. Influence of NaCl 0.9% infusion during plasmaphereses on IgG content in plasma. Transfus Med Hemother 2010;37:191-194.
– volume: 39
  start-page: 1266
  year: 1999
  end-page: 1270
  article-title: The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study
  publication-title: Transfusion
– volume: 27
  start-page: 117
  year: 2012
  end-page: 125
  article-title: Anticoagulation techniques in apheresis: from heparin to citrate and beyond
  publication-title: J Clin Apher
– volume: 41
  start-page: 1166
  year: 2001
  end-page: 1171
  article-title: Comprehensive analysis of citrate effects during plateletpheresis in normal donors
  publication-title: Transfusion
– volume: 37
  start-page: 191
  year: 2010
  end-page: 194
  article-title: Influence of NaCl 0.9% infusion during plasmaphereses on IgG content in plasma
  publication-title: Transfus Med Hemother
– volume: 15
  start-page: 230
  year: 2000
  end-page: 235
  article-title: Clinically relevant hypokalemia, and loss of hemoglobin and platelets during stem cell apheresis
  publication-title: J Clin Apher
– volume: 41
  start-page: 123
  year: 2014
  end-page: 133
  article-title: Donor hemovigilance during preparatory plasmapheresis
  publication-title: Transfus Med Hemother
– volume: 46
  start-page: 789
  year: 2010
  end-page: 795
  article-title: Apheresis affects bone and mineral metabolism
  publication-title: Bone
– year: 2015
– year: 2010
– ident: e_1_2_6_3_1
– ident: e_1_2_6_7_1
  doi: 10.1046/j.1537-2995.1999.39111266.x
– ident: e_1_2_6_10_1
  doi: 10.1046/j.1537-2995.2001.41091165.x
– ident: e_1_2_6_6_1
– ident: e_1_2_6_5_1
  doi: 10.1159/000317092
– ident: e_1_2_6_4_1
– ident: e_1_2_6_9_1
  doi: 10.1002/jca.21222
– ident: e_1_2_6_2_1
  doi: 10.1016/j.bone.2009.11.008
– ident: e_1_2_6_8_1
  doi: 10.1002/1098-1101(2000)15:4<230::AID-JCA3>3.0.CO;2-B
– ident: e_1_2_6_11_1
  doi: 10.1159/000357991
SSID ssj0009935
Score 2.1038043
Snippet Background: The purpose of this study was to describe the distribution of trisodium‐citrate 4% (TSC) anticoagulant (AC) between the product and the donors...
The purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors undergoing...
Background: The purpose of this study was to describe the distribution of trisodium-citrate 4% (TSC) anticoagulant (AC) between the product and the donors...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 59
SubjectTerms Adolescent
Adult
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Anticoagulants - blood
apheresis
Blood Donors
citrate
citrate infusion rate
citrate toxicity
Citrates - administration & dosage
Citrates - adverse effects
Citrates - blood
Cross-Over Studies
Female
Humans
Immunoglobulin G - blood
Infusions, Intravenous
Male
Middle Aged
plasmapheresis
Plasmapheresis - adverse effects
Plasmapheresis - methods
Prospective Studies
Young Adult
Title Distribution of citrate and citrate infusion rate during donor plasmaphereses
URI https://api.istex.fr/ark:/67375/WNG-ZPH43P3R-6/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjca.21403
https://www.ncbi.nlm.nih.gov/pubmed/26011445
https://www.proquest.com/docview/1756030973
https://www.proquest.com/docview/1760863084
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS91AEB7EQvGlrdXW06qkItKXaLK72eTgk3jpQTgiolRKYdlboLVN5Fyg-Oud2VxEsVD6lpBJsreZ-XZ39huA7cRlTrPEx1qyMhYyLeMh8zy2zufcWJH6hM47j8_k6EqcXmfXC7DfnYVp-CH6BTfSjGCvScG1me49kIb-xBk_I7Y5tL8Uq0WA6OKBOgr9bghfzClXmciGHatQwvb6Nx_5ohfUrH-eA5qPcWtwPCev4XtX5Cbe5GZ3PjO79u4Jm-N_1ukNvGoBaXTQjKBlWPDVW3g5brfcV2B8RNS6bVasqC4j-yMQ2ka6cv01DtM5LbtF4a45-hi5uqon0S3C89-ayAv81E9X4erk-PJwFLc5GGIrmOCxTkqbWpu4tEyEcF4U0uXo9l0u0Yzy0nhpTIZu0GujmSg5-jdZYoNzWRRGC_4OFqu68msQoeVwBB9Sz4YIA6UuUu2H0jttC-ZyM4DPXW8o2xKUU56MX6qhVmYKm0eF5hnAVi9627ByPCe0E7q0l9CTGwpjyzP19eyL-nY-EvycXyg5gPWuz1WrwVOFsErS9lOO3_nUP0bdow0VXfl6TjISZ4Q8KcQA3jdjpf8ZUbXhZDXDWoUe_3s51enhQbj48O-iH2EJkVsbPr4Oi7PJ3G8gOpqZzaAG9w8vCGs
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5qC-qL97ZHq0YR8SVtsrvZ5IAvpVqPtedQSotFkGVvAXtJyrmA-Oud2VxKpYL4lpBJsruzs_Pt7uw3AG8SlznNEh9rycpYyLSMh8zz2Dqfc2NF6hM67zyeyNGx2DvJTpbgfXcWpuGH6BfcyDLCeE0GTgvSW1esoac45WdEN3cLViijd5hQHV6RR6HnDQGMOWUrE9mw4xVK2Fb_6jVvtEIN-_MmqHkduQbXs3sfvneFbiJOzjYXc7Npf_3B5_i_tXoA91pMGm03neghLPnqEdwet7vuj2H8gdh128RYUV1G9kfgtI105fpr7KkLWnmLwl1z-jFydVVPo0tE6Bea-Av8zM-ewPHux6OdUdymYYitYILHOiltam3i0jIRwnlRSJej53e5xJGUl8ZLYzL0hF4bzUTJ0cXJElucy6IwWvBVWK7qyq9DhIOHIwSRejZEJCh1kWo_lN5pWzCXmwG869ShbMtRTqkyzlXDrswUNo8KzTOA173oZUPMcZPQ26DTXkJPzyiSLc_U18kn9e1gJPgBP1RyABud0lVrxDOFyErSDlSO33nVP0bzoz0VXfl6QTISJ4U8KcQA1prO0v-M2NpwvpphrYLK_15OtbezHS6e_rvoS7gzOhrvq_3Pky_P4C4CuTaafAOW59OFf45gaW5eBJv4DY84DIY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9RAEB9qC8UvWt-nbY0i4pe0m93NJkc_lZ7nWb3jKBZLEZbNPqCtJsc9QPzrnd08SqWC-C0hk2R3Z2bnt6_fALwhJjWKEhsrQV3MReLiPrUs1sZmrNA8scSfdx5PxOiUH5-lZ2tw0J6Fqfkhugk37xmhv_YOPjNu_5o09BJH_NSzzd2BDS5I7k16cHLNHYWBN-xfzHyyMp72W1ohQve7V28Eow3frj9vQ5o3gWuIPMP78K0tc73h5GpvtSz29K8_6Bz_s1JbcK9BpNFhbUIPYM2WD2Fz3Ky5P4LxwHPrNmmxospF-iIw2kaqNN012unKz7tF4a4--xiZqqzm0Qzx-Q_l2Qvswi4ew-nw_ZejUdwkYYg1p5zFijidaE1M4gjnxvJcmAzjvskE9qPMFVYURYpx0KpCUe4YBjjhsMGZyPNCcfYE1suqtM8gwq7DePyQWNpHHChUnijbF9YonVOTFT1412pD6oah3CfK-C5rbmUqsXlkaJ4evO5EZzUtx21Cb4NKOwk1v_L72LJUfp18kOfTEWdTdiJFD7ZbncvGhRcScZXw608ZfudV9xidz6-oqNJWKy-DhicYyXkPnta20v3Mc7XhaDXFWgWN_72c8vjoMFw8_3fRl7A5HQzl54-TTy_gLqK4Ziv5Nqwv5yu7g0hpWewGj_gNej0LPg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Distribution+of+citrate+and+citrate+infusion+rate+during+donor+plasmaphereses&rft.jtitle=Journal+of+clinical+apheresis&rft.au=Evers%2C+Josef&rft.au=Taborski%2C+Uwe&rft.date=2016-02-01&rft.eissn=1098-1101&rft.volume=31&rft.issue=1&rft.spage=59&rft_id=info:doi/10.1002%2Fjca.21403&rft_id=info%3Apmid%2F26011445&rft.externalDocID=26011445
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0733-2459&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0733-2459&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0733-2459&client=summon